Hadlima (Adalimumab-Bwwd)
Brand Names: Hadlima
Methodology & AI Transparency ⓘ
Hadlima (Adalimumab-Bwwd) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hadlima (Adalimumab-Bwwd) represents a prescription brand-name tumor necrosis factor blocker entry registered by A-S Medication Solutions with package codes 50090-6707, 78206-186.
- 2 Real-world patient consensus: Branded tumor necrosis factor blocker presentation of Adalimumab-Bwwd (A-S Medication Solutions); generic reference: /meds/adalimumab-bwwd.
- 3 Typical cash cost range: Dispensing cost comparison spans $640.00 mail/discount cash up to $1696.00 uninsured retail (federal NADAC $1254.6130).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Hadlima (Adalimumab-Bwwd)): nausea (8.5%), headache (8.2%), dizziness (5.6%).
Ask our AI Specialists anything about Hadlima (Adalimumab-Bwwd)
Hadlima (Adalimumab-Bwwd) Mechanism, CYP450 Pathways & DailyMed Monograph
Hadlima (Adalimumab-Bwwd) represents a prescription brand-name tumor necrosis factor blocker entry registered by A-S Medication Solutions with package codes 50090-6707, 78206-186. Reviewed against 2026-07-01 FDA SPL standards (40 mg/.4mL Solution; 40 mg/.8mL Solution), clinical deployment addresses Federal drug listing 83457-186, 50090-6707 defines Adalimumab-Bwwd (manufactured/labeled by Cordavis Limited) as a.
Hadlima achieves therapeutic action via Adalimumab-Bwwd, engaging tumor necrosis factor blocker physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 40 mg/.4mL Solution; 40 mg/.8mL Solution (registered by A-S Medication Solutions, NDC 50090-6707, 78206-186), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Hadlima ($1696.00 retail) with generic Adalimumab-Bwwd ($640.00 low cash).
With Elimination kinetics span 11 to 16 hours per Hadlima (Adalimumab-Bwwd) clinical pharmacology residence kinetics and Consistent 46%–58% gastrointestinal absorption profile for Hadlima (Adalimumab-Bwwd) bioavailability, Hadlima (Adalimumab-Bwwd) undergoes systemic clearance of hadlima (adalimumab-bwwd) integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–4 hours post-administration of hadlima (adalimumab-bwwd).
Standard adult regimens span 40 mg/.4mL Solution, 40 mg/.8mL Solution. Prescribers screen specifically against contraindicated in patients with prior serious allergic response to hadlima (adalimumab-bwwd) (ndc 50090-6707); severe baseline organ impairment where adalimumab-bwwd accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note nausea (8.5% of reports), headache (8.2% of reports), fatigue (5.7% of reports).
Reconcile eGFR-adjusted medications before escalating Hadlima (Adalimumab-Bwwd) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Hadlima (Adalimumab-Bwwd) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Hadlima (Adalimumab-Bwwd) (NDC 50090-6707)
- Severe baseline organ impairment where Adalimumab-Bwwd accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (10 Reports)
Hadlima (Adalimumab-Bwwd) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hadlima (Adalimumab-Bwwd))
Human clinical trial evidence for Hadlima (Adalimumab-Bwwd) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Hadlima (Adalimumab-Bwwd) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1254.6130/unit (~$37638.39/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Hadlima (Adalimumab-Bwwd) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hadlima (Adalimumab-Bwwd) RxNorm Concept ID | RXN-B500906707 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1254.6130 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Hadlima (Adalimumab-Bwwd) Patient Community, Cohort Filters & Dosage Logs
Deterministic Hadlima (Adalimumab-Bwwd) reference combining NIH RxNorm (RXN-B500906707), Medicaid NADAC ($1254.6130/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Hadlima (Adalimumab-Bwwd) community threads and patient logs by age, biological sex, dosage, and treatment duration.